A post-incorporation study on the use of palivizumab in the Brazilian public health system

Respiratory syncytial virus (RSV) is the main cause of lower respiratory disease in infants and children under five years of age. As there is no specific treatment for RSV infections, prophylaxis with the specific monoclonal antibody palivizumab (PVZ) has been widely recommended for high-risk cases...

Descripción completa

Detalles Bibliográficos
Autores principales: Batista, Joanna d’Arc Lyra, Ferreira, Maria Angélica Pires, Xavier, Cilene da Silva, de Souza, Ires Tarsila Alves, Cruz, Luciane Nascimento, Polanczyk, Carisi Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto de Medicina Tropical 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845933/
https://www.ncbi.nlm.nih.gov/pubmed/33533808
http://dx.doi.org/10.1590/S1678-9946202163005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845933/
https://www.ncbi.nlm.nih.gov/pubmed/33533808
http://dx.doi.org/10.1590/S1678-9946202163005

Ejemplares similares